(Washington, D.C.)—Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on yesterday’s decision by the Food and Drug Administration (FDA) to approve Inflectra, the second biosimilar approved in the United States. Inflectra will compete with Remicade to treat Crohn’s disease and rheumatoid arthritis, among other conditions.
“The FDA is taking important steps toward approving more biosimilars in the United States. Increasing competition through the approval of brand and generic drug competitors is the key to lowering prescription drug costs for consumers, employers, government programs, and others.
To further advance the use of biosimilars, the FDA should finalize an interchangeability policy that will allow for greater patient access to these important drugs.”